SCHEMBL18157071

SCHEMBL18157071

CCO/C(C)=N/OCC(=O)NC

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GAA P10253 3/20 0.35
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 2/20 0.34
KMT2A Q03164 1/20 0.33
HPGD P15428 2/20 0.32
POLB P06746 1/20 0.32
ALOX15 P16050 1/20 0.31
SOAT1 P35610 1/20 0.31
ESR1 P03372 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.30
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21234359 0.84 ALDH1A1 (0.35) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL1562639 0.82 LMNA (0.34) KDM4EALDH1A1LMNAHSD17B10GAA
SCHEMBL1562641 0.82 LMNA (0.34) KDM4EALDH1A1LMNAHSD17B10GAA
SCHEMBL15274457 0.80 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL10067023 0.79 ALDH1A1 (0.41) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL16984086 0.78 SMN1; SMN2 (0.39) KDM4EALDH1A1LMNAGAASMN1; SMN2
SCHEMBL16984323 0.77 SMN1; SMN2 (0.36) KDM4EALDH1A1LMNAGAASMN1; SMN2
SCHEMBL15277094 0.77 ALOX15 (0.43) KDM4EALDH1A1LMNAHSD17B10GAA
SCHEMBL10067022 0.74 MGAM (0.36) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL24981904 0.73 ALDH1A1 (0.39) KDM4EALDH1A1LMNAHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202965-A1 RADIOTRACER COMPOSITIONS AND METHODS GE HEALTHCARE LTD (GB) 2022-06-30 US disclosed
US-11311636-B2 Radiotracer compositions and methods GE HEALTHCARE LIMITED (GB) 2022-04-26 US disclosed
US-20210330824-A1 PURIFICATION METHOD AND COMPOSITIONS GE HEALTHCARE LTD (GB) 2021-10-28 US disclosed
US-20190275182-A1 RADIOTRACER COMPOSITIONS AND METHODS GE HEALTHCARE LIMITED (GB) 2019-09-12 US disclosed
US-10300156-B2 Radiotracer compositions and methods GE HEALTHCARE LIMITED (GB) 2019-05-28 US disclosed
US-20160303262-A1 PURIFICATION METHOD AND COMPOSITIONS GE HEALTHCARE LIMITED (GB) 2016-10-20 US disclosed
US-20160303263-A1 RADIOTRACER COMPOSITIONS AND METHODS GE HEALTHCARE LIMITED (GB) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190275182-A1 RADIOTRACER COMPOSITIONS AND METHODS MET, METTL14, MEN1 KDM4E 2261/4885ALDH1A1 4112/4885LMNA 3537/4885
US-20160303263-A1 RADIOTRACER COMPOSITIONS AND METHODS MET, METTL14, MEN1 KDM4E 2261/4885ALDH1A1 4112/4885LMNA 3537/4885
US-20210330824-A1 PURIFICATION METHOD AND COMPOSITIONS FOLH1, ANPEP, PAICS KDM4E 1334/4885ALDH1A1 2157/4885LMNA 2100/4885
US-20220202965-A1 RADIOTRACER COMPOSITIONS AND METHODS MET, METTL14, MEN1 KDM4E 2261/4885ALDH1A1 4112/4885LMNA 3537/4885
US-10300156-B2 Radiotracer compositions and methods MET, METTL14, MEN1 KDM4E 2261/4885ALDH1A1 4112/4885LMNA 3537/4885
US-11311636-B2 Radiotracer compositions and methods MET, METTL14, MEN1 KDM4E 2261/4885ALDH1A1 4112/4885LMNA 3537/4885
US-20160303262-A1 PURIFICATION METHOD AND COMPOSITIONS FOLH1, ANPEP, PAICS KDM4E 1334/4885ALDH1A1 2157/4885LMNA 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.